NCT05757700
Study of 19(T2)28z1xx TRAC-Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Lymphoma No drug interventions treatment 1 recruiting NCT01742988
Study to Assess the Safety, Tolerability and Pharmacokinetics of Fimepinostat (CUDC-907) in Patients With Lymphoma treatment 1 completed NCT02623920
Brentuximab Vedotin, Bendamustine, and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma treatment 2 withdrawn NCT04792489
DALY II USA/ MB-CART2019.1 for DLBCL treatment 2 recruiting NCT02348216
Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma treatment 1 / 2 completed NCT05733650
Expanded Access Program for Epcoritamab Not Available Not Available approved_for_marketing NCT03625037
First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma treatment 1 / 2 active_not_recruiting NCT04745559
Optimizing Cellular and Humoral Immunity by Vaccinating With PCV13 Before and After CAR-T Therapy treatment 2 recruiting NCT05619367
A Compassionate Use (CU) Program of Odronextamab Not Available Not Available available NCT06208735
CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies No drug interventions treatment 1 not_yet_recruiting NCT06458439
Epcoritamab-CAR T Cells for Large B-cell Lymphomas treatment 2 recruiting NCT04542824
Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With R/R B-NHL treatment 1 / 2 active_not_recruiting NCT04594642
A Study of AZD0486 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma treatment 1 recruiting NCT05544019
Study of SGR-1505 in Mature B-Cell Neoplasms No drug interventions treatment 1 recruiting NCT06544265
SynKIR-310 for Relapsed/Refractory B-NHL No drug interventions treatment 1 recruiting NCT06588205
Exploring the Clinical Impact of MYC Aberrations and Their Relationship with Microenvironment in Diffuse Large B Cell Lymphoma and High-Grade C Cell Lymphoma No drug interventions Not Available Not Available not_yet_recruiting NCT04257578
Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell Lymphoma treatment 1 / 2 recruiting NCT03656835
Nanochip Technology in Monitoring Treatment Response and Detecting Relapse in Participants With Diffuse Large B-Cell Lymphoma No drug interventions diagnostic Not Available recruiting NCT05455697
Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma treatment 1 / 2 recruiting NCT05890352
Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment treatment 2 recruiting NCT04855253
Study of E7777 Prior to Kymriah for R/R DLBCL treatment 1 / 2 recruiting NCT06287398
Epcoritamab (Epcor)-Containing Combination Salvage Therapy Followed by ASCT & Epcor Consolidation in Patients With Relapsed LBCL treatment 2 recruiting NCT05263583
Sepantronium Bromide for the Treatment of High-grade B-cell Lymphoma treatment 2 recruiting NCT03620578
DA-EPOCH-R Induction Followed by Nivolumab Consolidation in Newly Diagnosed MYC, BCL2 and/or BCL6 Rearranged HGBL treatment 2 active_not_recruiting NCT04836507
Study of Efficacy and Safety of CRC01 in Adult Large B-cell Lymphoma Patients treatment 1 / 2 recruiting NCT01809600
Retrospective Analysis of Rituximab-containing Immunochemotherapy for Burkitt's or Burkitt-like Lymphoma in Adults No drug interventions Not Available Not Available completed NCT04476459
Camrelizumab in Combination With Apatinib in Refractory and Relapsed DLBCL treatment 1 / 2 unknown_status NCT04058470
Toripalimab Plus Rituximab Followed by R-CHOP for Elderly Patients With Untreated Diffused B Cell Lymphoma treatment 1 / 2 recruiting NCT06026319
CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma treatment 1 recruiting NCT05256641
Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell Lymphoma treatment 1 / 2 recruiting NCT06550141
Emapalumab Prevention of CAR-T Cell Associated Toxicities treatment 2 not_yet_recruiting NCT04914741
A Multicentre, Parallel Arm, Open-label Trial of Frontline R-CHOP/Pola-RCHP and Glofitamab in Younger, Higher Risk Patients With Diffuse Large B Cell Lymphoma (DLBCL) treatment 1 / 2 active_not_recruiting NCT04933617
Copanlisib With Dose-Adjusted EPOCH-R in Relapsed and Refractory Burkitt Lymphoma and Other High-Grade B-cell Lymphomas treatment 1 terminated NCT03255096
A Study to Evaluate Safety, Pharmacokinetics, and Clinical Activity of Combination of RO6870810 and Venetoclax, With or Without Rituximab, in Participants With Relapsed/Refractory DLBCL and/or High-Grade B-Cell Lymphoma and/or High Grade B-Cell Lymphoma With MYC and/or BCL2 and/or BCL6 treatment 1 completed NCT05621096
Low Dose Radiation as Bridging Therapy in Relapsed B-Cell Non-Hodgkin Lymphoma treatment 1 recruiting NCT04358458
First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas treatment 1 / 2 terminated NCT04796857
Tislelizumab in Combination With Lenalidomide in Refractory and Relapsed Elderly Patients With Non-GCB DLBCL treatment 1 / 2 unknown_status NCT06249191
Mosunetuzumab With Chemotherapy for the Treatment of Patients With Untreated C-Myc Rearrangement Positive High Grade B Cell Lymphoma or Diffuse Large B Cell Lymphoma treatment 1 / 2 recruiting NCT06015880
Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma treatment 1 recruiting NCT03036904
Study of Venetoclax Plus DA-EPOCH-R for the Treatment of Aggressive B-Cell Lymphomas treatment 1 completed NCT06014762
P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies treatment 1 recruiting NCT05464329
Mosunetuzumab in Combination With Platinum-Based Salvage Chemotherapy in Autologous Stem Cell Transplant-Eligible Patients With Relapsed/Refractory Aggressive B Cell Lymphoma treatment 1 recruiting NCT04858568
Immune Responses to COVID-19 Vaccination in Lymphoma Patients No drug interventions Not Available Not Available completed NCT05660395
A Study to Evaluate the Pharmacokinetics and Safety of Loncastuximab Tesirine in Participants With Relapsed or Refractory Diffuse Large B-cell Lymphoma or High-grade B-cell Lymphoma With Hepatic Impairment (LOTIS-10) basic_science 1 recruiting NCT04503538
Telemedicine for Early Detection of Cytokine Release Syndrome and Neurotoxicity No drug interventions supportive_care Not Available withdrawn NCT05412290
Mosunetuzumab Consolidation Therapy After autoSCT in r/r Aggressive B Cell Lymphoma treatment 1 recruiting NCT03132584
Cyclophosphamide and Alemtuzumab In Lymphoma treatment 1 terminated NCT03995147
Pembrolizumab in Combination With Chemotherapy for Patients With Untreated B Cell Lymphoma treatment 2 recruiting NCT04300998
Study of CAR-T Therapy in Older Patients No drug interventions Not Available Not Available recruiting NCT04555811
FT596 With Rituximab as Relapse Prevention After Autologous HSCT for NHL treatment 1 completed NCT06343311
T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL) No drug interventions treatment 1 / 2 recruiting NCT04226937
DLBCL Interim Response Evaluation for Customised Therapy No drug interventions Not Available Not Available recruiting NCT04205838
Anakinra in Preventing Severe Chimeric Antigen Receptor T-Cell Related Encephalopathy Syndrome in Patients With Recurrent or Refractory Large B-cell Lymphoma prevention 2 recruiting NCT01859819
Treatment for Advanced B-Cell Lymphoma treatment 2 completed NCT06093841
Relmacabtagene Autoleucel as Second-Line Therapy in Adult Patients With Aggressive B-cell NHL treatment 2 not_yet_recruiting NCT04844086
RPM CD19-mbIL15-CAR-T Cells in Patient With Advanced Lymphoid Malignancies No drug interventions treatment 1 terminated NCT05834426
Omic Technologies Applied to the Study of B-cell Lymphoma for the Discovery of Diagnostic and Prognosis Biomarkers No drug interventions Not Available Not Available not_yet_recruiting NCT03837873
DLCL002 Protocol for Patients With High Risk Aggressive B-cell Lymphoma treatment 2 unknown_status NCT04479267
Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Previously Untreated Lymphoma treatment 2 recruiting NCT06004167
Adaptive Bridging RT in R/R B-cell Lymphoma (Pre-CAR T) No drug interventions treatment Not Available recruiting NCT04067414
Exploratory Study of CD19-targeted Chimeric Antigen Receptor T Cells(BZ019) for Relapsed and Refractory B-cell Lymphoma No drug interventions treatment 1 unknown_status